| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



* From the Department of Anesthesiology Yale University School of Medicine New Haven Connecticut USA, the
Department of Anesthesia St. Vincent's Hospital Dublin and the
Department of Human Anatomy Physiology University College Dublin Ireland.
Address correspondence to: Dr. Michael J. Griffin, Department of Anesthesiology, Yale University School of Medicine, 333 Cedar Street, New Haven, Connecticut 06520-8051, USA. Phone: 203-785-2802; Fax: 203-785-6664; E-mail: michael.griffin{at}yale.edu
| Abstract |
|---|
|
|
|---|
Methods: Endothelium-free rat aorta rings were exposed serially to 107M, 106M and 105M PE alone and subsequently in the presence of 2 MAC desflurane and halothane. Secondly, endothelium-free preparations were exposed to 106M PE serially in the presence of 0, 1, 2 and 3 MAC desflurane and halothane. Thirdly, using an endothelium-intact preparation, the effect of desflurane on PE-induced contraction was examined, in the presence or absence of NG-nitro-L-arginine (L-NNA), an inhibitor of constitutive and inducible NO synthase.
Results: Contraction amplitudes secondary to 106 and 105M PE in endothelium-free preparations were increased by 74% and 36% respectively (P <0.05) in the presence of 2 MAC desflurane compared to controls. In endothelium- free preparations, contraction amplitudes secondary to 106M PE were increased in the presence of 1 and 2 MAC desflurane by 32% and 18% respectively (P <0.05) and reduced by 16% in the presence of 3 MAC halothane (P <0.05). In endothelium-intact preparations an expected absolute increase in contraction amplitude occurred in the presence of L-NNA but the desflurane effect was detectable both in the presence and absence of L-NNA.
Conclusion: Our results suggest that desflurane may have a local vasoconstrictive effect independent of endothelium and NO synthase activity. The mechanism remains to be determined.
THE effect of volatile anesthetic agents on vascular smooth muscle contraction is complex and depends on the agonist used and the concentration of the inhalational agent.1 In addition, inhalational agents affect nerve conduction and synaptic transmission by sympathetic nerve fibres which innervate arterial and arteriolar smooth muscle walls.2 Norepinephrine is the main neurotransmitter at the vascular neuromuscular junction.2
Desflurane is a relatively new volatile anesthetic agent.3 A rapid increase in desflurane levels is associated with an acute increase in sympathetic neural outflow4,5 and with increased concentrations of circulating epinephrine and norepinephrine.4 The site(s) responsible for the mediation of these responses to desflurane remain(s) unclear (Figure 1
). Complete airway blockade, systemic lidocaine, and other forms of pharmacological prophylaxis, do not fully block the response.6,7 In addition, the hemodynamic changes can be blunted independently of the sympathetic outflow response to rapidly increased desflurane concentration.8 The interaction of desflurane locally with the action of
-agonists on vascular smooth muscle is unknown. The effect of halothane on vascular ring vasomotion responses as well as its interaction with endothelium-dependent vasodilatation has been well characterised.912 There has been extensive research in the last decade on the interaction of anesthetic agents with the endothelium.1,13,14 Inhalational agents inhibit endothelium-mediated vasodilation,912 but they do alter endothelium-dependent relaxation in agent- specific ways.15,16 The interaction of desflurane with the synthesis and action of endothelial nitric oxide (NO) remains unknown.
|
| Materials and methods |
|---|
|
|
|---|
|
Experimental protocols
After this period and with evidence of complete accommodation to the resting tension (i.e., no evidence of further relaxation) a dose-response relationship for PE for each preparation was elicited (n=16). A contraction was obtained initially with 107M PE followed by three to four washouts at ten-minute intervals with Krebs-Ringer bicarbonate solution. Further contractions were elicited with 106M and 105M PE using a similar washout protocol. The displacement was allowed to return to baseline before the next contraction was elicited. The response to PE was reproducible with repetitive administration of the agonist. A similar series of three contractions with 107105M PE in the presence of 2 MAC desflurane or halothane (randomized) delivered by a vaporizer was then performed, following an initial equilibration period of 15 min. After a washout period of 30 min a control contraction in response to 106M PE alone was elicited. After another washout period a further series of contractions in response to 107105M PE in the presence of 2 MAC of the agent not previously used were performed. One MAC of desflurane in the rat is 5.7%17 and 1 MAC of halothane is 0.82%.18 The experiment was completed by another control contraction with 105M PE following a washout period of 30 min. In order to evaluate the effect on basal tension, ten preparations were exposed to 2 MAC desflurane or halothane in the absence of PE for 30 min.
A second series (n=12) was performed to examine the effect of increasing concentrations of desflurane and halothane on PE-induced contractions. Based on the previous results, a concentration of 106M PE was felt to be the optimum concentration to investigate the presence or absence of an inhalational agent effect. Following preparation as detailed above, a contraction was elicited with 106M PE followed by three to four washouts at ten- minute intervals with physiological saline. The next contraction was elicited with 106M PE 15 min following the addition of 1 MAC desflurane or halothane (randomized) and again followed by three to four washouts at ten-minute intervals. Further contractions were elicited in a similar fashion with 106M PE following 15 min exposure to 2 MAC of the agent and subsequently to 3 MAC of the agent. It was ensured that the displacement returned to baseline after the washouts and before the next contraction was elicited. A control contraction in response to 106M PE alone was elicited following a 30-min washout period. Another series of three contractions with 106M PE, in the presence of 1, 2 and 3 MAC of the agent not previously used, were performed using a similar protocol. Finally, another control contraction in response to 106M PE alone was performed following a 30-min washout period.
The third series (n=8) was performed to compare the interaction between desflurane and PE in the presence of intact endothelium and normal or inhibited NO synthase. The preparation and washout protocol was as above and contractions were elicited serially with 106M PE in the presence of 0, 1, 2, 3 and 0 MAC desflurane. Both preparations were endothelium-intact and one was continuously exposed to 103M L-NNA, a constitutive and inducible NO synthase inhibitor particularly effective in rat aorta.19
For all experiments, the amplitude of each contraction was measured and converted from millivolts to milligrams using the calibration values obtained for each preparation.
Agent concentrations
Desflurane and halothane were delivered from a vaporizer in the circuit delivering the O2CO2 mixture to the bath. To determine the time of equilibration of desflurane and halothane, we used an agent analyzer (Datex Capnomac Ultima®, Helsinki, Finland) to measure the concentration of the agents in the bath above the Krebs-Ringer bicarbonate solution over 15 min. We found that desflurane concentrations were stable after three minutes and halothane concentrations stable after five minutes. We recorded the correlation between dialed agent concentrations and agent concentrations in the water bath at equilibrium with the Krebs-Ringer bicarbonate solution at five minutes.
Statistical analysis
Data were analyzed using multiple comparisons of repeated measurements corrected with the Bonferroni adjustment and repeated measures ANOVA with the Greenhouse-Geisser correction for multisample asphericity. Results are expressed as mean ± SEM. A P value <0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
|
|
|
|
| Discussion |
|---|
|
|
|---|
The direct smooth muscle effects of halothane and other inhalational agents have been clearly documented in tracheal and vascular smooth muscle.20,21 Contraction is inhibited by at least three mechanisms: suppression of contractility independent of [Ca++]i by interaction with contractile proteins, reduction of intracellular Ca++ release at low concentrations and by inhibition of voltage-and receptor-operated Ca++ channels at higher concentrations.20,2224 However, there is previous evidence that inhalational agents interact with different agonists in specific ways and interact selectively with particular vascular smooth muscle receptors. Halothane, but not isoflurane, for example, has been shown to have contractile effects in vascular tissues during specific conditions, possibly due to enhanced Ca++ release from intracellular Ca++ pools.2527
The sites responsible for the mediation of the sympathetic activation and catecholamine release in response to rapidly increased desflurane concentration remain unclear (Figure 1
).6 Alfentanil has been shown to effectively blunt the hemodynamic changes associated with rapid increases in inspired desflurane concentration, without reducing activation of the sympathetic nervous system.8 Therefore, the hypertension associated with a rapid increase in desflurane level may not be mediated solely by increased sympathetic outflow. The interaction of desflurane with PE, which we have demonstrated, suggests that a local interaction between desflurane and endogenous catecholamines or increased catecholamine release from adventitial nerve endings may occur. The fact that desflurane does not alter basal tension suggests that catecholamine release from nerve endings is not altered. However, further studies with measurement of catecholamine outflow or use of inhibitors of norepinephrine synthesis are required. Desflurane, like all inhalational agents, also has a direct smooth muscle inhibitory effect via a Ca++ mediated endothelium-independent pathway,21 which may explain the lesser effect found at 3 MAC.
The interaction of inhalational agents with the vascular endothelium is complex.13,14 Most studies suggest that inhalational agents inhibit vascular endothelium-dependent relaxation.912, 2830 There is evidence that isoflurane and halothane inhibit receptor- and Ca ++-activated NO synthase activity and may inhibit formation or release of NO.11,31,32 Other studies have demonstrated inhibition of endothelium-dependent relaxation by sevoflurane, probably secondary to interaction of oxygen free radicals with NO, and direct endothelium-independent vasodilatory action.16,33 Our results suggest that the absolute effect of desflurane on PE-induced contraction is less in the presence of intact endothelium and NO synthesis but that the mechanism is independent of NO as the overall pattern of the facilitatory effect is similar in the presence or absence of L-NNA.
Human in vivo studies have demonstrated that desflurane has a hemodynamic profile similar to isoflurane: tachycardia, hypotension and reduced systemic vascular resistance.34 Studies on chronically instrumented animals have demonstrated that desflurane causes less direct vasodilatation than isoflurane.35 In vivo studies have revealed a time factor in the sympathomimetic response to step increases in desflurane concentration.4,5 In vivo, desflurane acts on vasculature with intact endothelium and autonomic innervation. In addition, the shorter time course of this in vitro study compared to in vivo studies, may allow demonstration of transient sympathomimetic effects not detected in long-term in vivo studies. It is possible that desflurane has a dual or biphasic effect, stimulating contraction initially or at lower concentrations and inhibiting contraction later or at higher concentrations. It is clear that there are several sites of action of desflurane on the contraction mechanism.
In summary, we have demonstrated that desflurane facilitates 107105M PE-induced contraction of endothelium-free vascular smooth muscle and that the maximal facilitating effect of desflurane is at 1 MAC. In addition, the effect of desflurane on contraction amplitude is independent of the endothelium and the presence or absence of inhibitors of NO synthase. These data suggest that a local effect may partly mediate the hypertensive response to increased desflurane levels seen in vivo. Determination of the possible mechanism of this effect will require further investigation, in particular, investigation of catecholamine release, use of different agonists and pharmacological blockade of Ca++ channels and
and ß receptors.
| Footnotes |
|---|
Accepted for publication January 5, 2001.
| References |
|---|
|
|
|---|
2 Burnstock G. Integration of factors controlling vascular tone. Anesthesiology 1993; 79: 136880.[Medline]
3 Weiskopf RB. Implicatons of chemical and physical properties of desflurane for longer surgery. Anaesthesia 1995; 50(Suppl.): 913.
4 Weiskopf RB, Eger II EI, Noorani M, Daniel M. Repetitive rapid increases in desflurane concentration blunt transient cardiovascular stimulation in humans. Anesthesiology 1994; 81: 8439.[Medline]
5 Moore MA, Weiskopf RB, Eger II EI, Noorani M, McKay L, Damask M. Rapid 1% increases of end-tidal desflurane concentration to greater than 5% transiently increase heart rate and blood pressure in humans. Anesthesiology 1994; 81: 948.[Medline]
6 Muzi M, Ebert TJ, Hope WG, Robinson BJ, Bell LB. Site(s) mediating sympathetic activation with desflurane. Anesthesiology 1996; 85: 73747.[Medline]
7 Weiskopf RB, Eger II EI, Noorani M, Daniel M. Fentanyl, esmolol and clonidine blunt the transient cardiovascular stimulation induced by desflurane in humans. Anesthesiology 1994; 81: 13505.[Medline]
8 Yonker-Sell AE, Muzzi M, Hope WG, Ebert TJ. Alfentanil modifies the neurocirculatory responses to desflurane. Anesth Analg 1996; 82: 1626.[Abstract]
9 Uggeri MJ, Proctor GJ, Johns RA. Halothane, enflurane, and isoflurane attenuate both receptor- and non- receptor mediated EDRF production in rat thoracic aorta. Anesthesiology 1992; 76: 10127.[Medline]
10 Hart JL, Jing M, Bina S, Freas W, Van Dyke RA, Muldoon SM. Effects of halothane on EDRF/cGMP- mediated vascular smooth muscle relaxations. Anesthesiology 1993; 79: 32331.[Medline]
11 Blaise G, To Q, Parent M, Lagarde B, Asenjo F, Sauvé R. Does halothane interfere with the release, action, or stability of endothelium-derived relaxing factor/nitric oxide? Anesthesiology 1994; 80: 41726.[Medline]
12
Iranami H, Hatano Y, Tsukiyama Y, Yamamoto M, Maeda H, Mizumoto K. Halothane inhibition of acetylcholine-induced relaxation in rat mesenteric artery and aorta. Can J Anesth 1997; 44: 1196203.
13 Stowe DF, Ebert TJ. Neural and endothelial control of the peripheral circulation implications for anesthesia: part II, endothelium-mediated effects in the normal and diseased circulation. J Cardiothor Vasc Anesth 1996; 10: 15971.[Medline]
14 Johns RA. Endothelium, anesthetics, and vascular control. Anesthesiology 1993; 79: 138191.[Medline]
15
Nakamura K, Terasako K, Toda H, et al. Mechanisms of inhibition of endothelium-dependent relaxation by halothane, isoflurane, and sevoflurane. Can J Anaesth 1994; 41: 3406.
16
Yamaguchi A, Okabe E. Effect of sevoflurane on the vascular reactivity of rabbit mesenteric artery. Br J Anaesth 1995; 74: 57682.
17
Eger II EI, Johnson BH. Rates of awakening from anesthesia with I-653, halothane, isoflurane and sevoflurane: a test of the effect of anesthetic concentration and duration in rats. Anesth Analg 1987; 66: 97782.
18 Quasha AL, Eger II EI, Tinker JH. Determination and applications of MAC. Anesthesiology 1980; 53: 31534.[Medline]
19 Joly GA, Ayres M, Chelly F, Kilbourn RG. Effects of NG-methyl-L-arginine, NG-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 1994; 199: 14754.[Medline]
20
Tagliente TM, Evans PJ, Ben-Harari RR. Halothane- and enflurane-induced inhibition of phasic responses to carbachol in isolated guinea pig trachea. Anesth Analg 1992; 74: 8996.
21
Yamakage M, Kohro S, Kawamata T, Namiki A. Inhibitory effects of four inhaled anesthetics on canine tracheal smooth muscle contraction and intracellular Ca2+ concentration. Anesth Analg 1993; 77: 6772.
22 Akata T, Izumi K, Nakashima M. The action of sevoflurane on vascular smooth muscle of isolated mesenteric resistance arteries (part 2). Mechanisms of endothelium-independent vasorelaxation. Anesthesiology 2000; 92: 144153.[Medline]
23
Yamakage M, Hirshman CA, Croxton TL. Volatile anesthetics inhibit voltage-dependent Ca2+ channels in porcine tracheal smooth muscle cells. Am J Physiol 1995; 268: L18791.
24
Kakuyama M, Nakamura K, Mori K. Halothane decreases calcium sensitivity of rat aortic smooth muscle. Can J Anesth 1999; 46: 116471.
25 Boyle III WA, Maher GM. Endothelium-independent vasoconstricting and vasodilating actions of halothane on rat mesenteric resistance blood vessels. Anesthesiology 1995; 82: 22135.[Medline]
26
Tsuchida H, Namba H, Seki S, Fujita S, Tanaka S, Namiki A. Role of intracellular Ca2+ pools in the effects of halothane and isoflurane on vascular smooth muscle contraction. Anesth Analg 1994; 78: 106776.
27 Vinh VH, Enoki T, Hirata S, et al. Comparative contractile effects of halothane and sevoflurane in rat aorta. Anesthesiology 2000; 92: 21927.[Medline]
28 Jing M, Ling GSF, Bina S, Hart JL, Muldoon SM. Halothane attenuates nitric oxide relaxation of rat aortas by competition for the nitric oxide receptor site on soluble guanylyl cyclase. Euro J Pharm 1998; 342: 21724.
29 Johns RA, Tichotsky A, Muro M, Spaeth JP, Le Cras TD, Rengasamy A. Halothane and isoflurane inhibit endothelium-derived relaxing factor-dependent cyclic guanosine monophosphate accumulation in endothelial cell-vascular smooth muscle co-cultures independent of an effect on guanylyl cyclase activation. Anesthesiology 1995; 83: 82334.[Medline]
30
Tsuchida H, Seki S, Tanaka S, Okazaki K, Namiki A. Halothane attenuates the endothelial Ca2+ increase and vasorelaxation of vascular smooth muscle in the rat aorta. Br J Anaesth 2000; 84: 21520.
31 Zuo Z, Tichotsky A, Johns RA. Halothane and isoflurane inhibit vasodilatation due to constitutive but not inducible nitric oxide synthase. Implications for the site of anesthetic inhibition of the nitric oxide/guanylyl cyclase signaling pathway. Anesthesiology 1996; 84: 115665.[Medline]
32
Kirstetter P, Lagneau F, Lucas O, Krupa Y, Marty J. Role of endothelium in the modulation of isoflurane- induced vasodilatation in rat thoracic aorta. Br J Anaesth 1997; 79: 847.
33 Izumi K, Akata T, Takahashi S. The action of sevoflurane on vascular smooth muscle of isolated mesenteric resistance arteries (part 1). Role of endothelium. Anesthesiology 2000; 92: 142640.[Medline]
34 Weiskopf RB. Cardiovascular effects of desflurane in experimental animals and volunteers. Anaesthesia, 1995; 50(Suppl.): 147.
35 Pagel PS, Kampine JP, Schmeling WT, Warltier DC. Comparison of the systemic and coronary hemodynamic actions of desflurane, isoflurane, halothane, and enflurane in the chronically instrumented dog. Anesthesiology 1991; 74: 53951.[Medline]
This article has been cited by other articles:
![]() |
T. A. Stekiel, Z. J. Bosnjak, and W. J. Stekiel Effects of General Anesthetics on Regulation of the Peripheral Vasculature Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2003; 7(3): 311 - 331. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |